CA2550128C - Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases - Google Patents
Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases Download PDFInfo
- Publication number
- CA2550128C CA2550128C CA2550128A CA2550128A CA2550128C CA 2550128 C CA2550128 C CA 2550128C CA 2550128 A CA2550128 A CA 2550128A CA 2550128 A CA2550128 A CA 2550128A CA 2550128 C CA2550128 C CA 2550128C
- Authority
- CA
- Canada
- Prior art keywords
- hydrate
- salt
- substituted
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract 5
- -1 Pyrrolopyridine-substituted benzol Chemical class 0.000 title claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract 5
- 150000002367 halogens Chemical class 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 4
- 239000011737 fluorine Substances 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 239000000460 chlorine Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 9
- 238000011321 prophylaxis Methods 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000031295 Animal disease Diseases 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10357510.3 | 2003-12-09 | ||
| DE10357510A DE10357510A1 (de) | 2003-12-09 | 2003-12-09 | Heteroarylsubstituierte Benzole |
| PCT/EP2004/013430 WO2005058891A1 (de) | 2003-12-09 | 2004-11-26 | Pyrrolopyridin-substituierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2550128A1 CA2550128A1 (en) | 2005-06-30 |
| CA2550128C true CA2550128C (en) | 2012-09-11 |
Family
ID=34638534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2550128A Expired - Fee Related CA2550128C (en) | 2003-12-09 | 2004-11-26 | Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080249105A1 (https=) |
| EP (1) | EP1709043B1 (https=) |
| JP (1) | JP4889502B2 (https=) |
| CA (1) | CA2550128C (https=) |
| DE (2) | DE10357510A1 (https=) |
| ES (1) | ES2317073T3 (https=) |
| WO (1) | WO2005058891A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| JP2010514695A (ja) | 2006-12-21 | 2010-05-06 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物および方法およびそのための適応症 |
| CL2007003874A1 (es) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| MY172424A (en) | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| CN106220623A (zh) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US8530444B2 (en) * | 2010-06-01 | 2013-09-10 | Aposense Ltd. | Pharmaceutical compounds |
| US9192680B2 (en) | 2010-06-01 | 2015-11-24 | Aposense Ltd. | Pharmaceutical compounds |
| US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| CN102603740B (zh) * | 2012-03-01 | 2014-05-14 | 南京药石药物研发有限公司 | 4-硝基-7-氮杂吲哚的合成方法 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| US12048761B2 (en) | 2015-10-13 | 2024-07-30 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| GEP20207202B (en) * | 2017-01-30 | 2020-12-25 | Chiesi Farm Spa | Tyrosine amide derivatives as rho-kinase inhibitors |
| EP3638670B1 (en) | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| US20240174683A1 (en) | 2021-02-05 | 2024-05-30 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| WO2025224050A1 (en) | 2024-04-22 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of patients suffering from hypomelanosis of ito |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| WO2002022856A2 (en) * | 2000-09-13 | 2002-03-21 | Schering Corporation | Uses of the mammalian ccl18 and related reagents |
| AU9598601A (en) * | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| UY27224A1 (es) * | 2001-03-23 | 2002-10-31 | Bayer Corp | Inhibidores de la rho-quinasa |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| JP4505228B2 (ja) * | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| EP1470121B1 (en) * | 2002-01-23 | 2012-07-11 | Bayer HealthCare LLC | Pyrimidine derivatives as rho-kinase inhibitors |
| MXPA04007196A (es) * | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| AU2003220935A1 (en) * | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
| ES2273047T3 (es) * | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| DE102004020570A1 (de) * | 2004-04-27 | 2005-11-24 | Bayer Healthcare Ag | Substituierte Phenylaminopyrimidine |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2003
- 2003-12-09 DE DE10357510A patent/DE10357510A1/de not_active Withdrawn
-
2004
- 2004-11-26 JP JP2006543421A patent/JP4889502B2/ja not_active Expired - Fee Related
- 2004-11-26 EP EP04798090A patent/EP1709043B1/de not_active Expired - Lifetime
- 2004-11-26 CA CA2550128A patent/CA2550128C/en not_active Expired - Fee Related
- 2004-11-26 US US10/582,184 patent/US20080249105A1/en not_active Abandoned
- 2004-11-26 DE DE502004008604T patent/DE502004008604D1/de not_active Expired - Lifetime
- 2004-11-26 ES ES04798090T patent/ES2317073T3/es not_active Expired - Lifetime
- 2004-11-26 WO PCT/EP2004/013430 patent/WO2005058891A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20080249105A1 (en) | 2008-10-09 |
| WO2005058891A1 (de) | 2005-06-30 |
| DE10357510A1 (de) | 2005-07-07 |
| DE502004008604D1 (de) | 2009-01-15 |
| EP1709043A1 (de) | 2006-10-11 |
| JP4889502B2 (ja) | 2012-03-07 |
| JP2007513901A (ja) | 2007-05-31 |
| CA2550128A1 (en) | 2005-06-30 |
| ES2317073T3 (es) | 2009-04-16 |
| EP1709043B1 (de) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2550128C (en) | Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases | |
| JP2007513901A5 (https=) | ||
| ES2795366T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
| AU2004249511B2 (en) | Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives | |
| TWI250978B (en) | New compounds | |
| MX2011008379A (es) | Compuestos de 3-arilquinazolin-4-ona para combatir plagas de invertebrados. | |
| WO2005060963A8 (en) | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity | |
| CA2706991A1 (en) | Heteroaryl-substituted piperidines | |
| KR20160115933A (ko) | Irak4 억제제로서의 인다졸 화합물 | |
| WO2004083167A1 (ja) | スルファミド誘導体及びその医薬組成物 | |
| UA92083C2 (ru) | Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом | |
| CA2403686A1 (en) | Substituted piperidines as melanocortin receptor agonists | |
| NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
| WO2004004730A3 (en) | 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders | |
| JP7342025B2 (ja) | 抗マラリア性ヘキサヒドロピリミジン類似体 | |
| WO2008133734A4 (en) | Method and compositions for treating hiv infections | |
| CN104411682B (zh) | 用于制备立体选择性环氧酮化合物的方法 | |
| CA2494352A1 (en) | Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 achr agonists | |
| WO2003099763A8 (en) | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | |
| ZA958438B (en) | Crop protection products | |
| WO2004081011A1 (en) | Immunomodulating heterocyclic compounds | |
| CA2653666A1 (en) | Aryl-substituted heterocycles and their use | |
| WO2004106295A3 (en) | Substituted piperodines and pyrrolidines as calcium sensing receptor modulators and method | |
| SA518391540B1 (ar) | حاصرات قنوات الصوديوم | |
| MXPA02004555A (es) | Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141126 |